Skip to main content
Praxis Precision Medicines, Inc. logo

Praxis Precision Medicines, Inc. — Investor Relations & Filings

Ticker · PRAX ISIN · US74006W2070 US Manufacturing
Open in API
Filings indexed 458 across all filing types
Latest filing 2023-12-07 Capital/Financing Update
Country US United States of America
Listing US PRAX

About Praxis Precision Medicines, Inc.

https://praxismedicines.com/

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company that develops therapies for central nervous system (CNS) disorders. The company's methodology involves translating insights from genetic epilepsies into treatments for conditions characterized by neuronal excitation-inhibition imbalance. Praxis employs a genetics-focused approach, utilizing translational tools and patient-guided development strategies to advance its portfolio. The developmental pipeline includes several clinical-stage assets and numerous early-stage programs designed to address complex brain disorders.

Recent filings

Filing Released Lang Actions
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report pursuant to the Securities Exchange Act of 1934. The content describes the entry into a material definitive agreement, specifically an Open Market Sale Agreement for an 'at the market' equity offering program. It includes details about the agreement, parties involved, and related exhibits such as the agreement itself and legal opinion. There are no financial statements or comprehensive financial data typical of annual or quarterly reports. The document is an announcement of a financing activity rather than a full financial report. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is 6443 characters, sufficient to contain substantive information about the financing event, not just a brief announcement or a certification. Hence, the classification is CAP with high confidence.
2023-12-07 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) under the Securities Act of 1933. It details an offering of common stock up to $75 million through an at-the-market offering with Jefferies LLC as the sales agent. The content includes offering details, risk factors, use of proceeds, dividend policy, plan of distribution, and legal matters. This type of document is a capital raising disclosure related to financing activities, not a financial report, earnings release, or management discussion. Therefore, it fits the category of Capital/Financing Update filings.
2023-12-07 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by Praxis Precision Medicines, Inc. It reports a corporate action: a 1-for-15 reverse stock split of common stock effective November 28, 2023. The document includes a Certificate of Amendment to the Certificate of Incorporation and updated unaudited selected financial data adjusted for the reverse stock split. The report references prior filed Annual Report on Form 10-K and Quarterly Reports on Form 10-Q but does not contain full financial statements or detailed financial analysis itself. The primary purpose is to announce the reverse stock split and provide related updated financial data, not to present a full financial report. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as stock splits or reverse splits. The document length (6608 characters) and content confirm it is a substantive filing, not merely an announcement of a report (RPA) or a regulatory filing (RNS). Therefore, the correct classification is CAP with high confidence.
2023-12-01 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, titled 'Current Report' and dated November 20, 2023. It reports the approval and details of a reverse stock split of the company's common stock, including the ratio, effective date, and trading symbol changes. The content focuses on a corporate action related to capital structure (reverse stock split) and does not contain financial statements or earnings data. The document is about a capital structure change announcement rather than a full financial report or earnings release. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is 6310 characters, which is sufficient for a substantive announcement rather than a brief notice. Hence, the classification is CAP with high confidence.
2023-11-22 English
10-Q
Interim / Quarterly Report Q3 2023
2023-11-07 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 7, 2023, reporting the financial results for the quarter ended September 30, 2023. It specifically states that it is furnishing a press release with the quarterly financial results. The document length is 3579 characters, which is relatively short and primarily serves as an announcement of the earnings release rather than containing detailed financial statements or substantive financial data itself. According to the 'MENU VS MEAL' rule, such a document is classified as an Earnings Release (ER) since it announces quarterly financial results and includes a press release. The document is not a full quarterly report (IR) because it does not contain comprehensive financial data, only a summary announcement and a press release. Therefore, the correct classification is Earnings Release (ER) with high confidence.
2023-11-07 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.